Market Size of Global Epigenetics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 16.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Epigenetics Market Analysis
The epigenetics market is projected to register a CAGR of 16.1% during the forecast period (2022-2027).
Covid has significantly impacted the epigenetics market growth due to the importance of epigenetics in COVID-19 research. For instance, according to the study published in Clinical Epigenetics, titled 'The epigenetic implication in coronavirus infection and therapy' in October 2020, epigenetic alterations might play an essential role in the onset of coronavirus disease complications. Although numerous treatment options are being investigated, further research is urgently needed to discover a viable vaccine or safer chemotherapeutic medications, including epigenetic therapies, to combat this viral pandemic and create pre-and post-exposure COVID-19 prophylaxis. This will lead to increased adoption of epigenetics in discovering therapies for COVID-19 infection, thereby expected to drive the market growth over the forecast period.
Factors such as the rising prevalence of cancers, rise in funding in research and development in healthcare, and rising applications of non-oncological applications of epigenetics, among others, are expected to drive the market growth over the forecast period.
As per Globocan 2020, there were 19,292,789 new cancer cases were reported worldwide. This worldwide and extensive cancer threat remains a major driver for developing new cancer therapies that help in risk assessment, early diagnosis, and effective treatment monitoring.
In addition, rising healthcare research and development expenditure across the globe is further expected to drive the growth of this market over the forecast period. For instance, according to the World Health Organization in December 2021, the gross domestic research and development expenditure on health (health GERD) as a percentage of gross domestic product (GDP) in high-income countries is 0.21%. For upper middle and low-income countries, it is 0.02%. Such huge investments in healthcare research and development will drive market growth due to adopting epigenetics in research.
On the other hand, the high cost of epigenetics and the dearth of skilled professionals in epigenetic research is expected to hamper the market studied.
Epigenetics Industry Segmentation
As per the scope of this report, epigenetics, in simple terms, refers to the study of genetic effects that are not entirely encoded by the DNA sequence of an organism. Epigenetics mainly deals with gene expression. Epigenetics also refers to changes in the genome in terms of functionality, which do not involve changes in the nucleotide sequence. DNA methylation or histone modification is a mechanism that causes epigenetic changes. The Epigenetics Market is segmented by Product (Instruments, Kits, and Reagents, Others), Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases), Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Product | |
| Instruments | |
| Reagents & Kits | |
| Others |
| By Application | |
| Oncology | |
| Autoimmune Diseases | |
| Metabolic Diseases | |
| CNS/Pain Diseases | |
| Cardiovascular Diseases | |
| Others |
| By Technology | |
| Methylation | |
| Acetylation | |
| Phosphorylation | |
| Other Technologies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Epigenetics Market Size Summary
The epigenetics market is experiencing significant growth, driven by its critical role in healthcare research, particularly in cancer and COVID-19 studies. The market's expansion is fueled by the increasing prevalence of cancer, which necessitates the development of new therapies for risk assessment, early diagnosis, and effective treatment monitoring. Additionally, the rising investments in healthcare research and development globally are propelling the market forward. The adoption of epigenetics in non-oncological applications further contributes to this growth. Despite challenges such as high costs and a shortage of skilled professionals, advancements in DNA methylation technologies and increased funding for research are expected to bolster market development.
In North America, the market is poised for substantial growth due to significant investments in cancer genomics and the high prevalence of cancer, which drives the demand for better diagnostics and therapeutics. The presence of major regional players and ongoing investments in epigenetics research and development further support market expansion. The competitive landscape is characterized by major players focusing on expanding their portfolios through strategic collaborations and acquisitions. This dynamic environment presents opportunities for both new entrants and established companies to capitalize on the growing demand for epigenetics solutions.
Global Epigenetics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidence and Prevalence of Cancer
-
1.2.2 Increasing Funding for R&D in Healthcare
-
1.2.3 Rising Epigenetic Applications in Non-oncology Diseases
-
-
1.3 Market Restraints
-
1.3.1 Rising Costs of Instruments
-
1.3.2 Dearth of Skilled Researchers
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product
-
2.1.1 Instruments
-
2.1.2 Reagents & Kits
-
2.1.3 Others
-
-
2.2 By Application
-
2.2.1 Oncology
-
2.2.2 Autoimmune Diseases
-
2.2.3 Metabolic Diseases
-
2.2.4 CNS/Pain Diseases
-
2.2.5 Cardiovascular Diseases
-
2.2.6 Others
-
-
2.3 By Technology
-
2.3.1 Methylation
-
2.3.2 Acetylation
-
2.3.3 Phosphorylation
-
2.3.4 Other Technologies
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Global Epigenetics Market Size FAQs
What is the current Global Epigenetics Market size?
The Global Epigenetics Market is projected to register a CAGR of 16.10% during the forecast period (2024-2029)
Who are the key players in Global Epigenetics Market?
Abcam PLC, Active Motiff, Illumina Inc., Diagenode Inc. and Merck KGaA are the major companies operating in the Global Epigenetics Market.
